Issue link: http://clhia.uberflip.com/i/834345
c The Committee made multiple submissions to OSFI on reinsurance issues related to draft versions of LICAT supplied to the CLHIA. We were particularly successful in getting vital changes needed for issues related to unregistered reinsurance. Electronic Claims and Anti-fraud c Both Phases 1 and 2 of the industry's new centralized Provider Alert Registry (PAR) were launched, which provides the opportunity for those CLHIA members agreeing to the terms of use to participate. The CLHIA also continues to lead the discussions on a pilot project for pooling claims data at an industry level to identify suspicious claims that may not have been noticeable based on an individual insurer's own block of business. Good progress has been made and a decision to proceed is expected by end of May 2017. c With respect to electronic claims matters, the CLHIA continues to lead the work to develop a governance model with all stakeholders that would support the ongoing maintenance and updating of the existing pharmacy claims standard. Work also continues to finalize an updated national dental agreement by working closely with the Canadian Dental Association (CDA) and the Association des chirurgiens dentistes du Québec (ACDQ). CLHIA Statistical Reporting Review c The CLHIA's 2016 Factbook publication was completely redesigned to improve content and format so that it provides more clear, user friendly and relevant information to readers. The 2016 version includes more trend analysis and illustrations to highlight key data/ information, including new data on the pay-out ratio for health insurance, federal and provincial tax contributions, and the industry's global footprint. To date, the feedback received has been very positive. Industry Advocacy c The CLHIA held its 7 th federal Industry Advocacy Day in Ottawa and its 2 nd Advocacy Day in Quebec. Both events saw solid participation from our member CEOs and resulted in several high-level meetings with key Cabinet Ministers, MPs and senior officials on the files that are at the top of our industry's priority list including: lower prescription drug prices for Canadians, infrastructure and international trade. We also made several appearances to provide testimony on behalf of the industry at both federal and provincial standing committees on key issues impacting the industry, for example: A Message from the President and CEO Board of Directors Review of the Year's Results CLHIA Code of Member Service Members CLHIA Officers Chair's Message